Argireline is a six-amino-acid peptide, sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, sold as a cosmetic ingredient under the INCI names acetyl hexapeptide-3 and acetyl hexapeptide-8 (the two names refer to the same molecule). It was described in a 2002 paper by Blanes-Mira and colleagues and commercialized by Lipotec, now part of Lubrizol, which holds the Argireline trademark. You'll find it in serums and creams sold around the "topical Botox" idea. It is a topical cosmetic, not an injectable drug.
What it's supposed to do
The peptide is a fragment of SNAP-25, a protein in the SNARE complex that nerve cells use to release neurotransmitters. In the lab, Argireline competes with native SNAP-25 and interferes with assembly of the SNARE complex. A defective complex can't drive the calcium-dependent vesicle fusion that releases the transmitter, so the signal telling a muscle to contract is dampened. That is the same general step botulinum toxin blocks, which is where the comparison comes from. The original Blanes-Mira study framed it as a biosafe alternative to botulinum toxins for cosmetic use.
Two things keep that comparison honest. The peptide is far weaker than the toxin, by orders of magnitude in potency. And botulinum toxin is injected directly where it acts, while Argireline has to cross the skin from a topical product to reach anything.
What the research shows
The foundational evidence is the 2002 paper. An oil-in-water emulsion containing 10% of the hexapeptide, used on healthy women volunteers, reduced wrinkle depth by up to 30% after 30 days by skin-topography measurement, alongside in-vitro data on neurotransmitter release.
A 2025 systematic review in the Journal of Drugs in Dermatology pulled together the human literature: 10 studies, 312 participants, through August 2024. All ten reported some decrease in wrinkle or scar prominence, and no significant adverse effects were reported in any trial. But the reviewers were candid about quality. Many studies were small, used mixed-ingredient formulations rather than the peptide alone, and varied in how they measured results. There is no head-to-head clinical trial against botulinum toxin, and the large double-blind randomized trials you'd want for a strong efficacy claim aren't there.
The other caveat is getting the molecule to its target. A peptide that works by reaching nerve endings has to first get through the stratum corneum, and Argireline is hydrophilic and not small for skin penetration. Penetration work cited in the literature found that the great majority of applied peptide stays at or near the surface, with only a tiny fraction reaching the viable epidermis. That gap between what happens in a cuvette and what happens on a face is the central open question, and it's why some formulators pair it with delivery systems or modified analogs.
Regulatory and quality notes
Argireline is regulated as a cosmetic ingredient, not as an approved drug, and is used topically in over-the-counter products. It is not a controlled substance and is not on WADA's prohibited list. Anti-aging cosmetic claims are not the same as drug efficacy claims, and nothing here is medical or dosing advice.
For anyone sourcing the raw peptide rather than a finished cosmetic, identity and purity are the things to verify. Acetyl hexapeptide-3/8 has well-defined identifiers (DrugBank DB11709) that a certificate of analysis should match. A COA showing the intended sequence and a mass-spec / HPLC purity figure from the seller, ideally backed by independent third-party testing, is the meaningful check, since the suppliers in this market vary widely. peptideone aggregates vendor COAs and third-party rater signals so those claims can be compared rather than taken on faith.